ArticleJournal of virology2013
Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.Scientific reports · 2024Pooled it
- The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- The Sigma1 ER membrane receptor promotes structural protein folding and genome packaging of dengue virus.PLoS pathogens · 2026Article
- Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes.JHEP reports : innovation in hepatology · 2023Article
- Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies.Archives of microbiology & immunology · 2023Article
- Review
- Overview of the potential use of fluvoxamine for COVID-19 and long COVID.Discover mental health · 2023Review
- Endomembrane remodeling in SARS-CoV-2 infection.Cell insight · 2022Review
- Mechanisms of action of fluvoxamine for COVID-19: a historical review.Molecular psychiatry · 2022Review
- Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.International journal of molecular sciences · 2022Review
- Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy.PloS one · 2022Article
- Targeting Selective Autophagy as a Therapeutic Strategy for Viral Infectious Diseases.Frontiers in microbiology · 2022Review
- Monitoring reversion of hepatitis C virus-induced cellular alterations by direct-acting antivirals using cryo soft X-ray tomography and infrared microscopy.Acta crystallographica. Section D, Structural biology · 2021Article
- Cellular host factors for SARS-CoV-2 infection.Nature microbiology · 2021Review
- Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy.Expert opinion on therapeutic targets · 2021Review
- Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of S1R Activation and Its Role in Neurodegenerative Diseases.International journal of molecular sciences · 2021Article
- Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.Frontiers in pharmacology · 2021Article
- Article
- Targeting Crucial Host Factors of SARS-CoV-2.ACS infectious diseases · 2020Review
- A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals.Journal of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Hepatitis C virus (HCV) genome replication is thought to occur in a membranous cellular compartment derived from the endoplasmic reticulum (ER). The molecular mechanisms by which these membrane-associated replication complexes are formed during HCV infection are only starting to be unraveled, and both viral and cellular factors contribute to their formation. In this study, we describe the discovery of nonopioid sigma-1 receptor (S1R) as a cellular factor that mediates the early steps of viral RNA replication. S1R is a cholesterol-binding protein that resides in lipid-rich areas of the ER and in mitochondrion-associated ER membranes (MAMs). Several functions have been ascribed to this ER-resident chaperone, many of which are related to Ca(2+) signaling at the MAMs and lipid storage and trafficking. Downregulation of S1R expression by RNA interference (RNAi) in Huh-7 cells leads to a proportional decrease in susceptibility to HCV infection, as shown by reduced HCV RNA accumulation and intra- and extracellular infectivity in single-cycle infection experiments. Similar RNAi studies in persistently infected cells indicate that S1R expression is not rate limiting for persistent HCV RNA replication, as marked reduction in S1R in these cells does not lead to any decrease in HCV RNA or viral protein expression. However, subgenomic replicon transfection experiments indicate that S1R expression is rate limiting for HCV RNA replication without impairing primary translation. Overall, our data indicate that the initial steps of HCV infection are regulated by S1R, a key component of MAMs, suggesting that these structures could serve as platforms for initial RNA replication during HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.